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a b s t r a c t
Achieving tight glycaemic control early following the diagnosis of type 2 diabetes is key
to optimising clinical outcomes, yet many patients and clinicians are reluctant to initiate
and intensify insulin therapy. Reasons for this arise primarily from a lack of time, clinical
expertise and patient understanding. However, meaningful progress can be achieved with
self-management educational programmes soon after diagnosis. Clinician education and
training, along with easy-to-use and well-tolerated therapies (for example, those carrying a
low risk of hypoglycaemia and/or avoiding weight gain), may also increase the likelihood of
patient adherence.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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1. Introduction
Currently, 387 million people worldwide are living with dia-
betes, of whom 3.9 million are in the UK [1]. The majority
remain in poor glycaemic control and at risk of vascular com-
plications, which may already be developing at the time of
diagnosis [2,3].
The UK Prospective Diabetes Study (UKPDS) revealed that
intensive diabetes management from diagnosis was associ-
ated with a reduced risk of microvascular complications by
the end of the 10-year trial period [4], and a reduced risk
of myocardial infarction and all-cause death reported in the
decade following [5]. Subsequent shorter-term landmark trials
that recruited patients at high risk of cardiovascular disease
(CVD)with a long duration of diabetes, and that involved strin-
gent glycaemic targets andmore complex treatment regimens
in the intensive arm, did not show such clear-cut beneﬁts
in terms of macrovascular complications and mortality [6].
All the trials demonstrated a reduced risk of microvascular
complications (some more substantial than others) but only
UKPDS demonstrated a reduced risk of macrovascular disease
and mortality at the end-of-trial (reaching signiﬁcance in the
10-year follow-up) [5]. Follow-up of the Veterans Affairs Dia-
betes Trial (VADT) for almost 10 years revealed a reduced risk
of cardiovascular event but not all-cause mortality in partici-
pants from the intensive treatment arm [7]. Results from these
trials demonstrate the importance of individualising treat-
ment targets (according to established vascular complications
and comorbidities [2]) and suggest that delayed treatment
intensiﬁcation can allow irreversible diabetes-related com-
plications to develop. The latest results from a retrospective
cohort study conﬁrm this, since a 1-year delay in treatment
intensiﬁcation inuncontrolledpatients signiﬁcantly increased
the risk of myocardial infarction, heart failure, stroke and a
composite endpoint of cardiovascular events (Fig. 1) [8].
The current guidelines recommend stepwise intensiﬁca-
tion [2,3], and while resistance to intensiﬁcation is evident at
every step, it appears to be more pronounced when consider-
ing initiating insulin [9], despite this being the most effective
agent for lowering blood glucose when used appropriately
[2]. Furthermore, few patients intensify their insulin regimen
appropriately [10,11]. The failure to close the gap between best
practice and the patient’s usual level of care is termed ‘clinical
inertia’ [12].
The majority of clinical inertia studies are focused on the
US, the UK and Canada. In the present study, we review the
evidence for clinical inertia in the UK, where healthcare is free
for all, and also the barriers and potential solutions.
2. Methods
A focused literature search for studies on clinical inertia relat-
ing to insulin initiation and intensiﬁcation in patients with
type2diabetes in theUKwas conductedusingPubMed, Scopus
and Google Scholar. Search terms included ‘type 2 diabetes’,
‘insulin intensiﬁcation’, ‘delay’, ‘time’, ‘inertia’, ‘insulin avoid-
ance’, ‘escalation’ and ‘reluctance’. Only studies conducted
in the UK were included. Table 1 illustrates some of the key
studies [9,10,13–18].
3. What evidence is there of clinical inertia?
Studies show that insulin initiation is delayed until after mul-
tiple oral antidiabetic drug (OAD) failures and deterioration of
glycaemic control well beyond recommended guidelines [19].
Clinical inertia is not restricted to the UK, as demonstrated by
results of the Study of Once Daily Levemir (SOLVETM; Table 1)
[11,13]. Reasons why blood glucose levels were higher in the
UK at the time of insulin initiation were not reported.
Relatively few studies examine clinical inertia with insulin
intensiﬁcation, but results show similar delays (Table 1). A
retrospective analysis of data from insulin-treated patients
with type 2 diabetes within The Health Improvement Network
(THIN) UK primary care database demonstrated that intensi-
ﬁcation was associated with high HbA1c (mean 77mmol/mol
[9.2%] before change) and longer duration of diabetes, whereas
lack of intensiﬁcation was associated with an increased risk
of co-morbidities. The proportion of patients who intensiﬁed
basal insulin or switched to prandial/premixed insulin had a
mean HbA1c of 71mmol/mol (8.6%) and 69mmol/mol (8.5%)
following change in therapy, respectively. This is in contrast
to the mean HbA1c values that were achieved by participants
of phase 3 clinical trials investigating these prandial or premix
insulin analogues [10].
A retrospective cohort study of 11,696 insulin-treated UK
patients revealed that 31% of patients who were clinically eli-
gible for intensiﬁcation (HbA1c of 58mmol/mol [≥7.5%]) were
treated accordingly (Table 1) [18]. Older age, longer duration
of diabetes and higher Charlson comorbidity index were all
associated with a longer time to intensiﬁcation, which might
be expected given that less stringent HbA1c targets are rec-
ommended for these populations [2,3]. However, only a small
reduction in time to intensiﬁcation was observed when apply-
ing a less stringent HbA1c cut-off of ≥64mmol/mol (8.0%) to
the same entire study population. Use of OADs also had a sig-
niﬁcant association with time to intensiﬁcation, correlating
with a longer delay; yet receiving≥2OADswas associatedwith
a reduced delay versus receiving one OAD [18].
Results from a multinational survey, ‘Management Of
Diabetes In Future Years’ (MODIFY), revealed that 30% of
primary care physicians overall never/rarely personally inten-
siﬁed insulin (compared with 4% of specialists), despite 92%
of physicians agreeing with the statement “insulin intensi-
ﬁcation is an essential element of diabetes management”.
However, it is not known whether any of these primary care
physicians were lacking the necessary resources for insulin
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Table 1 – Studies reporting clinical inertia for insulin therapy in the UK.
Study Number of patients Key ﬁndings
Khunti et al. [13] UK cohort of SOLVE (n=761) At the time of insulin initiation, the UK cohort had a higher baseline HbA1c compared with the global
population of SOLVE (84mmol/mol [9.8%] vs. 74mmol/mol [8.9%], respectively), despite a shorter
duration of disease
Mata-Cases et al. [14] 2783 Of 997 not achieving glycaemic targets, only 66.8% intensiﬁed, with an even smaller proportion of them
initiating insulin treatment (3.7%). Mean HbA1c values in patients for whom treatment intensiﬁed vs
non-intensiﬁed were 68mmol/mol (8.4%) vs. 66mmol/mol (8.2%), p<0.05.
Khunti et al. [9] 81,573 Retrospective cohort study on patients with type 2 diabetes in Clinical Practice Research Datalink looked
at time to treatment intensiﬁcation in those receiving one, two or three OADs. Mean HbA1c at
intensiﬁcation with an OAD or insulin for people taking one, two or three OADs was 72mmol/mol (8.7%),
76mmol/mol (9.1%) and 83mmol/mol (9.7%). Median time to intensiﬁcation with insulin was >7.1, >6.1 or
6.0 years, respectively.
Evans et al. [15] 128,568 Retrospective cohort-based study revealed that mean HbA1c at insulin initiation was 80mmol/mol (9.5%)
(one OAD), 81mmol/mol (9.6%) (two), 83mmol/mol (9.7%) (three) and 87mmol/mol (10.1%) (four), with
insulin initiated only after there had been an average increase in HbA1c of 8mmol/mol (0.7%).
Calvert et al. [16] 14,824 people on DIN-LINK
database included
Study examined the extent of monitoring and glycaemic control in patients with type 2 diabetes
prescribed oral agents and/or insulin, and investigated transition to insulin. Only 34% had HbA1c
assessments 6 months before and after initiation of their last oral therapy. Of the patients with HbA1c
assessments, 62% had evidence of poor glycaemic control following therapy. Median time to insulin for
patients prescribed multiple oral agents was 7.7 years.
Zografou et al. [17] 509 Retrospective study examining patients who initiated insulin therapy between 2002 and 2011 from the
Scottish Care Information-Diabetes Collaboration (SCI-DC) database (Scotland). Patients spent a median
period of 49 (0–325) months with HbA1c > 53mmol/mol (>7%), 25 (0–163) months with
HbA1c >64mmol/mol (>8%) and 10 (0–135) months with HbA1c >75mmol/mol (>9%), and concluded that
healthcare professionals delay the initiation of insulin in patients with type 2 diabetes until their HbA1c
exceeds 86mmol/mol (10%). As a result, patients are exposed to a signiﬁcant glycaemic burden.
Blak et al. [10] 4045 Retrospective cohort study on patients in The Health Improvement Network (THIN) database who
initiated insulin for the ﬁrst time between 2004 and 2006. Of 3815 patients followed up, the initial insulin
regimen remained unchanged for 75.1%, while 13.7% discontinued, 7% switched and only 4.7%
intensiﬁed, despite only 17.3% of patients achieving glycaemic target <53mmol/mol (7%).
Khunti et al. [18] 11,696 31% of patients in the UK Clinical Practice Research Datalink database receiving basal insulin therapy
between 2004 and 2011 who were clinically eligible for treatment intensiﬁcation were treated
accordingly. Of the 37% of patients who did have treatment regimens intensiﬁed, 50%, 43% and 7% were
intensiﬁed with bolus insulin, premix insulin or GLP-1RAs, respectively. The median time to
intensiﬁcation was 4.3 years [4.1; 4.6]95%CI from basal insulin initiation in all patients and 3.7 years [3.4;
4.0]95%CI from the time HbA1c ≥7.5% was recorded.
CI, conﬁdence interval; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; OAD, oral antidiabetic drug.
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Fig. 1 – Consequences of delayed intervention in patients without previous CVD.
The risk of CVD is shown for patients with HbA1c consistently above 53mmol/mol (7%) in the 2 years following diagnosis
for whom treatment intensiﬁcation is delayed by at least 1year versus that of patients with HbA1c consistently below
53mmol/mol (7%) in the same period [8].
CI, conﬁdence interval; CVD, cardiovascular disease; CVE, cardiovascular event; HbA1c, glycated haemoglobin; HF, heart
failure; IT, intensiﬁcation of treatment; MI, myocardial infarction.
Illustration based on data from Paul et al. [8]. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
intensiﬁcation and so referred patients to a specialist [20]. A
total of 95% of physicians cited “excessive levels of HbA1c”
as a key indicator to consider intensiﬁcation, but it was not
reported to what extent the time their patients spent uncon-
trolled contributed to their decision [21].
To summarise, these studies demonstrate that current
guidelines are largely not being adhered to.
4. Do the current guidelines help?
The proportion of people with diabetes uncontrolled on their
current therapy seems at oddswith thewide range of effective
antidiabetic therapies now available. However, the challenge
is to consolidate the plethora of clinical trial and real-world
data into a clear set of guidelines on how to manage diabetes
both effectively and economically.
The key points of the joint American Diabetes Association
(ADA)/European Association for the Study of Diabetes (EASD)
statement [2] and the National Institute for Health and Care
Excellence (NICE) guidelines [3] regarding timely achievement
of glycaemic control in type 2 diabetes are summarised in
Table 2.
The NICE guidelines [3] advise treatment escalation when
HbA1c rises to >58mmol/mol (>7.5%) until control is achieved,
implying that clinicians should be content with HbA1c of
between 48 and 58mmol/mol (6.5–7.5%) even in patients for
whom 48mmol/mol (6.5%) would be a suitable target. Little
information is offered regarding the time a patient should
spend at hyperglycaemia before treatment intensiﬁcation.
This propagates a reactive approach wherein clinicians wait
for the worsening of hyperglycaemia or complications to arise
before intensifying treatment, and patients will likely reach
glycaemic targets for only short periods, if at all (Fig. 2) [22].
The joint statement update issued from ADA/EASD [2],
however, does provide clear timelines of up to 3 months for
escalation.
The detrimental effect that variation between the
ADA/EASD and NICE guidelines could have on clinician adher-
ence to guidelines has been discussed elsewhere [23]. Between
2000 and 2007, the mean HbA1c of insulin users with type 2
diabetes in the UK reduced by only 1mmol/mol (0.1%) from
69mmol/mol (8.5%) to 68mmol/mol (8.4%), despite – and in
contrast to – the NICE and ADA/EASD guidelines introduced
during this period [24].
The guidelines also have a number of drawbacks in com-
mon, an unavoidable one being that they quickly become
out of date because of the constantly changing landscape of
diabetes treatment. In addition, both guidelines recommend
stepwise addition of therapy according to HbA1c levels. This
approach often fails to correct the underlying pathophysio-
logical defects of type 2 diabetes [25]. While the therapeutic
beneﬁt of a medication must be balanced against its ﬁnan-
cial cost, the focus on cost-effectiveness by NICE has been
criticised as short-sighted in view of the risk of diabetic com-
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Table 2 – A comparison of the current guidelines for type 2 diabetes [2,3].
EASD/ADA NICE
Targets Recommends lowering HbA1c to <53mmol/mol (<7%) in
most patients to reduce the incidence of microvascular
disease. More stringent HbA1c targets (e.g.
42–48mmol/mol [6–6.5%]) might be considered in
selected patients (short disease duration, long life
expectancy, no signiﬁcant CVD) if this can be achieved
without signiﬁcant hypoglycaemia or other adverse
events. Conversely, less stringent HbA1c goals (e.g.
58–64+mmol/mol [7.5–8%+]) are appropriate for
patients with a history of severe hypoglycaemia, limited
life expectancy, advanced complications, extensive
comorbid conditions and those in whom the target is
difﬁcult to obtain despite “best efforts according to
guidelines”
Set a target HbA1c level of 48mmol/mol (6.5%) for most
adults with type 2 diabetes that is managed either by
lifestyle and diet, or by lifestyle and diet in combination
with a single drug that is not associated with
hypoglycaemia. For adults receiving a drug associated
with hypoglycaemia, aim to achieve HbA1c of
53mmol/mol (7.0%). If HbA1c levels are not adequately
controlled by a single drug and rise to ≥58mmol/mol
(7.5%), intensify drug treatment, set a target HbA1c of
53mmol/mol (7.0%) and reinforce advice about diet,
lifestyle and adherence to drug treatment. Consider less
stringent HbA1c targets (∼53–58mmol/mol [7.0–7.5%]) in
appropriate cases, similar to those outlined in
ADA/EASD statement [2].
Treatment While encouraging therapeutic lifestyle change is
important at diagnosis, periodic counselling should also
be integrated into the treatment programme. Insulin is
a possible ﬁrst intensiﬁcation step of metformin in the
two-drug combination tier depending on patient- and
disease-speciﬁc factors present. Addition of a third
drug, namely TZD, DPP-4i, SGLT2i or GLP-1RA, is then
recommended if the patient remains uncontrolled.
Similarly, addition of insulin to those uncontrolled on
metformin+GLP-1RA is another recommendation. More
complex insulin strategies are ultimately recommended
if the combinations above fail
Sensible recommendations regarding lifestyle, patient
education, monitoring and targets. Insulin
recommended as the second intensiﬁcation of drug
treatment only. GLP-1RAs are only recommended in
patients if triple therapy with metformin and two other
oral drugs is not effective, not tolerated or
contraindicated, and who either would beneﬁt from
weight loss or for whom insulin therapy would have a
signiﬁcant occupational impact. Lacking clear
information regarding intensiﬁcation of insulin,
particularly with OADs. A limited number of insulin
intensiﬁcation strategies are included in the NICE
algorithm: switching to pre-mix insulins; or
intensiﬁcation with a GLP-1RA (with specialist support)
or an SGLT2i.
Timelines If HbA1c target not achieved after ∼3 months of therapy,
add additional therapy
Lacking explicit guidelines, with the exception of
stopping rules for GLP-1RA and pioglitazone.
Recommends testing HbA1c levels every 3–6 months
until stable on unchanged therapy, and every 6 months
thereafter.
CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated
haemoglobin; SGLT2i, sodium-glucose co-transporter-2 inhibitor; TZD, thiazolidinedione.
plications later in life [26]. Therefore, the task of tackling
clinical inertia should be kept in mind when updating the
guidelines.
While there is certainly room for improvement in the
guidelines, particularly those from NICE, the evidence sug-
gests that clinical inertia in the UK is also caused by a lack
of adherence to any of the available guidelines.
5. Why is there clinical inertia?
5.1. Clinician-level barriers
Barriers to treatment intensiﬁcation can be divided into those
at the patient, clinician or system level, and the majority of
these barriers were discussed in a set of interviews conducted
for a UK-based qualitative study [27].
A major clinician-level hurdle is a limited awareness of
clinical inertia, resulting in overestimation by clinicians of
their quality of care and adherence to guidelines [12,19]. This
issue may be exacerbated as the management of chronic
diseases increasingly becomes a primary care responsibility
because insulin therapy requires specialist training and more
patient-contact time than OAD therapy.
Development of vascular complications increases the
patient’s risk of mortality and it is therefore important to
address increases inHbA1c and risk factors for CVD, as demon-
strated by the Steno-2 study [28]. However, GPs may not be
familiar with the current opinion that aggressive control early
on following diagnosis leads to signiﬁcant beneﬁt in appropri-
ate patients [27]. As a result, the precious time GPs do have is
often focused on their patients’ current HbA1c and cholesterol
levels, aswell as their bloodpressure andmeetingQualityOut-
comes Framework targets, rather than the glycaemic burden
caused by the duration of poor glucose control [17].
Patients with multimorbidity are common and pose a
major challenge [29], with respect to balancing the beneﬁt of
lowering blood glucose against the risk of adverse side effects
in these patients. Following results from VADT, ADVANCE and
ACCORD, andasdocumented in a key studybyCurrie et al. [30],
the fear of adverse side effects impacts the decisions made by
patients and clinicians. In a global survey of 1250 physicians,
including 150 from the UK, 75.5% reported that they would
intensify treatment more readily if it were not for concerns
about hypoglycaemia [31].
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Fig. 2 – Median time to intensiﬁcation and mean HbA1c at intensiﬁcation in patients with type 2 diabetes currently treated
with one or two OADs with intensiﬁcation to two OADs or insulin, respectively.
OAD, oral antidiabetic drug.
Republished with permission of Medinews (Cardiology) News Ltd, from Campbell IW, Br J Cardiol 2000;7:625–31; permission
conveyed through Copyright Clearance Center, Inc. Adapted with permission from Del Prato et al. [22], with data from
Khunti et al. [9].
Other clinician-level barriers stem from their concerns
over patient adherence, perceiving their patients as unable
or unwilling to adapt to the increasingly complex regimen.
Results from a questionnaire revealed that fear of injection
pain was a low-ranking factor for patients considering insulin
therapy, whereas family physicians perceived this to be a
major patient concern [32]. The belief that patients will refuse
to initiate/intensify insulin therapy is a major cause of psy-
chological insulin resistance [33], and the results from this
questionnaire suggest it might be untrue.
These barriers are exacerbated by the lack of time available
to GPs to adequately tackle concerns.
5.2. Patient-level barriers
There are several misperceptions about insulin therapy
(reviewed in Polonsky et al. [34]) that are more frequently con-
tributory factors for insulin-naïve versus insulin-experienced
patients [35], suggesting that further educationon these issues
would resolve them [27]. Problematic patient beliefs include
the belief that insulin therapy is not efﬁcacious [36], that their
quality of life will drop considerably [35,36], and that they
will not be able to adhere to increasingly complex regimens
[36]. Patient fear of unwanted side effects such as weight
gain and hypoglycaemia [31,34,35], and of injection pain [37],
can also delay intensiﬁcation. Insulin-experienced patients,
unsurprisingly, do not view insulin regimens to be as highly
burdensome as do insulin-naïve patients, until multiple injec-
tions are involved [37].
In a systematic review of factors affecting adherence to
insulin therapy [38], positive predictors of insulin adherence
included diabetic nurse specialist support; switching to a pen
device; hypoglycaemia awareness; experience of liaison psy-
chiatry or cognitive behavioural therapy; and lower perceived
consequences of diabetes/higher perception of personal con-
trol. Negative predictors included a large number of injections,
female gender and lower HbA1c. However, few of these predic-
tors were consistently reported across studies included in the
systematic review.
Self-reported rates of adherence also varied across these
studies from 43–86% [38]. Another study revealed that one-
third of patients reported insulin omission on at least one
day in the last month, while three-quarters of physicians
reported that their patients did not take insulin as prescribed
[31]. These discrepancies highlight the problem with objec-
tive assessment of adherence (i.e. it is difﬁcult to deﬁne and
is perceived differently according to the questions posed and
background knowledge).
A more objective, although arguably less informative, out-
put is the proportion of patients who discontinue insulin
therapy. Among 6072 insulin-treated patients in the UK Clin-
ical Practice Research Datalink database, 32.1% stopped basal
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insulin therapy. Reasons for stopping were unknown [18].
Pscherer et al. [39] compared persistence after 2 years with
treatment regimens involving insulin glargine, insulin detemir
or neutral protamine Hagedorn insulin in combination with
either a prandial insulin or an OAD. In basal–oral therapy reg-
imens, 2-year persistence varied from 53% to 65%, whereas
in intensiﬁed conventional therapy, persistence was around
85%. Reasons for discontinuation are unknown, but predic-
tors for discontinuation included type of insulin, diabetic
co-medication and patient characteristics (diagnosed heart
failure). In a small US study (N=1563 patients uncontrolled
on insulin), 97 patients discontinued insulin therapy and 157
did not initiate therapy [40]. The most common reason for
discontinuation was injection-related concerns (74%), with
47.1% of ‘discontinuers’ and 86.1% of ‘non-initiators’ doing so
on a healthcare professional’s (HCP’s) advice. Further details
regarding the HCPs’ reasons were not available but this high-
lights how patient and clinician barriers overlap [40].
6. What can we do to overcome clinical
inertia?
6.1. Tackling clinician barriers
The shift of responsibility from secondary care to primary
care in the UK necessitates extra resources for GPs. This
may be in the form of formal education, assistance from
nurses and informed feedback. In the US, non-insulin-treated
patients with hypertension and type 2 diabetes (N=157)
beneﬁted from a signiﬁcant improvement in mean HbA1c
(−8mmol/mol [−0.7%], p=0.02) and high-density lipoprotein
cholesterol (+2.6mg/dL, p=0.02) when a new disease manage-
ment programme was implemented by a nurse practitioner
and physician duo, versus usual care by a physician [41]. These
ﬁndings are supported by several other studies that describe
more timely treatment intensiﬁcation when GPs are assisted
by nurses [19].
Perhaps a simpler avenue proposed for tackling clinician
barriers is setting up channels of computer-based direction
and/or specialist feedback to assist GPs [42]. For example,
signiﬁcantly more clinicians who were supported with an
automated decision support tool and/or an educational DVD
in a randomised controlled trial (RCT) correctly identiﬁed a
glycaemic anomaly and proceeded with the appropriate treat-
ment regimen [43].
Other methods to support GPs have included case manage-
ment with a practice nurse or pharmacist directing treatment
decisions according to an approved, detailed treatment algo-
rithm under the supervision of a physician, and automated
appointment reminders for patients [42].
6.2. Tackling patient-level barriers
Rectifying the issue of inadequate patient education and
impaired communication between the patient and HCP
involves a great deal of time [19]. Therefore, time-saving
educational strategies such as self-management programmes
that empower andequip thepatient tomanage their bloodglu-
cose have been investigated. Promising results were reported
in a systematic review with meta-analyses that evaluated
the effect of group-based diabetes self-management educa-
tion (DSME) [44]. This systematic review revealed that DSME
was associated with a signiﬁcant reduction in HbA1c at 6
months (0.44%points; p=0.0006, 13 studies, 1883participants),
and this reduction was maintained at 2 years (0.87% points;
p<0.00001, 3 studies, 397 participants) according to RCTs con-
ducted up to January 2008 [44].
Clinical trials have demonstrated signiﬁcantly greater
reductions in HbA1c versus that of usual care when a Diabetes
Education and Self-Management for Ongoing and Newly Diag-
nosed (DESMOND) model of education was coupled with an
intensive treatment regimen in patients referred fromUKgen-
eral practices and specialist clinics [45]. In patients with type
2 diabetes and microalbuminuria, randomisation to intensive
intervention with a structured DESMOND model of patient
education yielded signiﬁcant improvements in HbA1c, blood
pressure and cholesterol versus that of usual care. Impor-
tantly, this tight control was achieved with a lower incidence
of moderate and severe hypoglycaemia. It therefore appears
that the DESMOND model had equipped patients to optimise
their self-management with an intensive treatment regimen,
thus providing evidence that effective education is important
in helping to overcome clinical inertia. NICE has stated that
a structured educational programme is recommended, with
regular updates to reinforce this learning [3], but the cost-
effectiveness of this approach has yet to be determined.
More basic patient education should begin as early in the
disease trajectory as possible to dispel the idea that insulin
represents ‘the end of the road’ [33]. Explaining, at diagno-
sis, that the progressive nature of type 2 diabetes means that
the majority of patients will eventually require insulin could
tackle the perception that insulin therapy represents a fail-
ure in diabetes management [33]. Indeed, the joint ADA/EASD
statement does not consider insulin therapy to be the last
resort, and does not denote any preference in the order of
treatments after lifestyle changes and metformin [2].
6.3. Tackling therapeutic barriers
Another way in which clinical inertia is continually addressed
is by the development of new therapeutic options that have
minimal effect on the patient’s quality of life. In pursuit of this
goal, longer-acting insulinswith a lower risk of hypoglycaemia
have been developed [46].
Additionally, combining insulin analogues with the newer
classes of drugs has widened the options for intensiﬁcation.
Inhibitors of the sodium-glucose-linked transporter-2 protein
(SGLT2i), which is responsible for the majority of renal glu-
cose absorption, are the newest class of OADs to become
available. They achieve a reduction in both HbA1c and body
weight, and are associated with a low risk of hypoglycaemia
[2,47]. Glucagon-like peptide-1 receptor agonists (GLP-1RAs)
and inhibitors of the protease dipeptidyl peptidase-4 (DPP-
4) are also both associated with a low risk of hypoglycaemia
because of their glucose-dependent effects. Both would also
be of interest to patients with concerns regarding body weight
as DPP-4 inhibitors are weight-neutral and GLP-1RAs promote
weight loss [2].
10 pr imary care d iabetes 1 1 ( 2 0 1 7 ) 3–12
Insulin analogues can be intensiﬁed with GLP-1RAs and
vice versa to combine the clinical advantages of, and mitigate
the side effects associated with, the individual components
[2]. Fixed-ratio products, such as insulin degludec/liraglutide
(IDegLira) and lixisenatide/insulin glargine (LixiLan), enable
such a combination to be given with a single daily injection,
simplifying the regimen for patients [48–50].
To summarise, multiple therapy options have recently
become available, enabling individualisation of type 2 dia-
betes treatment. However, older medications that may be less
effective, such as sulphonylureas [2,3], remain in widespread
use [51,52] and are promoted by the guidelines, often because
of their lower costs. Physicians may resist prescribing newer,
more appropriate therapies because of a lack of knowledge,
experience and conﬁdence in prescribing these medications.
Therefore, it is important for post-marketing studies to
focus on real-world evidence, training programmes and cost-
effectiveness, and for the guidelines to be updated regularly so
that they reﬂect the full range of therapeutic options available,
to facilitate appropriate use in clinical practice.
7. Conclusion
Clinical inertia with insulin intensiﬁcation in diabetes is a
chronic problem globally, although more so in the UK, despite
the availability of a wide range of new therapies as outlined
in the ADA/EASD and NICE guidelines. There is insufﬁcient
focus, particularly in the new NICE guidelines, on how long
a patient should remain uncontrolled before intensiﬁcation of
treatment. Overcoming clinical inertia also requires education
of patients as to the long-term beneﬁts of lowering their blood
glucose and how best to achieve this. This will likely necessi-
tate further education ofHCPs in the formof formal training as
well as professional feedback, togetherwith increased nursing
support. Finding the time, funding and human resources (par-
ticularly of nursing staff) to overcome these barrierswill be the
greatest challenge, particularly in the current economic and
political climate, so research should continue to evaluate the
most cost-effective means of tackling clinical inertia. This will
encourage patients and HCPs to use the best available therapy
option appropriately.
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